Clinical Trial Update: Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating L-Ornithine L-Aspartate as an adjunct to BCAA-enriched solutions for Hepatic Encephalopathy in ICU patients; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Encephalopathy

Drugs mentioned

• Branched-Chain Amino Acids (BCAA) enriched solutions (branched-chain amino acids)
• L-Ornithine L-Aspartate (LOLA) (L-ornithine-L-aspartate)

Snippet

Sponsor: Ain Shams University | Conditions: Hepatic Encephalopathy | Phase 4 | Status: COMPLETED